Why You Should Buy This Undervalued Stock Before Everyone Else Does
Oftentimes, finding undervalued needles in the proverbial haystack means seeking out businesses with acknowledged problems but reasonable prospects of a steadier, less troublesome future. If Walgreens Boots Alliance (NASDAQ: WBA) fits this description, the company's shares could revisit their early-2022 peak.
Granted, it takes guts to invest in a stock that shed 27% of its value in 2022's first half. Walgreens has certainly faced its share of problems lately, but the company is faring reasonably well, given the circumstances. In time, Wall Street might favor Walgreens again -- but by then, the stock price should already have recovered.
Along with the usual worries over high inflation and supply chain issues, Walgreens has had company-specific headwinds to deal with this year. Among them is a $683 million charge resulting from Walgreens' opioid settlement in Florida, as well as 2022's sharp demand reduction for COVID-19 test kits and vaccinations. As the omicron crises came and went, Walgreens went from administering 11.8 million vaccinations in fiscal 2022's second quarter to just 4.7 million in Q3.
Source Fool.com
